More Invex Therapeutics Ltd. news
Invex Therapeutics Ltd.ASX: IXC

First UK Clinical Site Activated in IIH EVOLVE Phase 3 Trial

Oct 23, 2022 at 10:42 PM EDT · Issued by Invex Therapeutics Ltd.

Filed with ASX · Oct 23, 2022 at 10:42 PM EDT · 3 pages · English

On 6ix: 6ix.com/news/first-uk-clinical-site-activated-in-iih-evolve-phase-3-trial

Invex Therapeutics Ltd. on 6ix

In the deck

  • Invex Therapeutics — Argonaut Biotech Briefing (October 2022)16 slidesOct 26, 2022

Story so far

  • First Australian Site Activated in IIH EVOLVE Phase 3Oct 24, 2022
  • Second HREC Approval for IIH EVOLVE Phase III Clinical TrialSep 30, 2022
  • Invex Receives UK Approval to Commence Phase III TrialJun 29, 2022

Earlier from Invex Therapeutics

  • First Australian Site Activated in IIH EVOLVE Phase 3Oct 23, 2022
  • Second HREC Approval for IIH EVOLVE Phase III Clinical TrialSep 29, 2022
  • 4E and Annual Report to shareholdersAug 18, 2022
  • Invex receives IND approvalAug 18, 2022
  • Quarterly Activities/Appendix 4C Cash Flow ReportJul 5, 2022

Later from Invex Therapeutics

  • Invex Receives $0.46 Million R&D Tax RebateOct 31, 2022
  • First Patient Randomised in IIH EVOLVE Phase III TrialNov 20, 2022
  • MEDSAFE and Ethics Approval for IIH EVOLVE Trial in NZNov 24, 2022
  • Invex Receives Approval for Paediatric Plan from the EMADec 13, 2022
  • First US Clinical Site Activated in IIH EVOLVE Phase IIIJan 18, 2023
All Invex Therapeutics news releases↗

Follow Invex Therapeutics into a list and get an email when it puts out news.

Follow Invex Therapeutics
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer